title: Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life.
abstract: The cost-effectiveness of treatments that have the potential to change the "natural history" of a chronic progressive disease has to be evaluated over the long term. Cost-effectiveness estimates have been based on the concept that, with treatment, patients will not progress to the next level(s) of disease severity or will take a longer time to progress, thus avoiding or delaying the high costs and low utility associated with more severe disease. This analysis focused on the use of Rituximab in treating patients with moderate to severe RA for whom at least one anti-TNFα blocking agent had failed. The aim of our study was to evaluate the cost-effectiveness in 32 patients with rheumatoid arthritis in therapy with a single infusion of Rituximab 1,000 mg given on days 1 and 15 of each month for 1 year. After 6 months of treatment, we observed for all 32 patients a total quality-adjusted life year (QALY) gained of 11,840 with an average of 0.37 QALY for a single patient, a treatment cost of euro 5,610 and a QALY/cost ICER (incremental cost-effectiveness ratio) of euro 15,114. After 1 year of treatment, we observed data for 28 patients with a total QALY gained of 11,480 with an average of 0.41 QALY for a single patient, a treatment cost of euro 9,690 and a QALY/cost ICER (incremental cost-effectiveness ratio) of euro 23,696. The benefit of using Rituximab is cost-effectiveness with a QALY/gained under the acceptable threshold of euro 50,000 in our observational study. These are important data for discussion from the economic point of view when we choose a biologic therapy for rheumatoid arthritis in clinical practice.
authors.affiliation: Rheumatology Unit, Department of Internal Medicine, Ospedale di S. Giovanni di Dio, Azienda Sanitaria di Firenze, Via Torregalli 3, 50143 Florence, Italy. maubenucci@tiscali.it
authors.forename: Maurizio
authors.initials: M
authors.lastname: Benucci
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Saviola
authors.forename: Paola
authors.initials: P
authors.lastname: Baiardi
authors.forename: Mariangela
authors.initials: M
authors.lastname: Manfredi
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000191:economics / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006304:Health Status; D006801:Humans; D007596:Joints / Q000473:pathology / Q000503:physiopathology; D008297:Male; D017063:Outcome Assessment, Health Care; D019057:Quality-Adjusted Life Years; D020127:Recovery of Function; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab
references.citation: Rheumatology (Oxford). 2008 Apr;47(4):507-13
references.pmid: 18304941
references.citation: Ann Rheum Dis. 2004 Jan;63(1):4-10
references.pmid: 14672883
references.citation: J Health Econ. 1986 Mar;5(1):1-30
references.pmid: 10311607
references.citation: Rheumatology (Oxford). 2000 Oct;39(10):1159-61
references.pmid: 11035144
references.citation: Clin Exp Rheumatol. 2010 Sep-Oct;28(5):722-7
references.pmid: 20883636
references.citation: Arthritis Rheum. 2002 Sep;46(9):2310-9
references.pmid: 12355478
references.citation: Clin Exp Rheumatol. 2002 Jul-Aug;20(4):505-15
references.pmid: 12175106
references.citation: Joint Bone Spine. 2008 Dec;75(6):688-95
references.pmid: 18951825
references.citation: Arthritis Rheum. 2007 May;56(5):1417-23
references.pmid: 17469098
references.citation: Arthritis Rheum. 1980 Feb;23(2):137-45
references.pmid: 7362664
references.citation: Scand J Rheumatol. 2007 May-Jun;36(3):179-83
references.pmid: 17657670
references.citation: Int J Technol Assess Health Care. 2009 Apr;25(2):181-9
references.pmid: 19331709
references.citation: Curr Med Res Opin. 2008 Sep;24(9):2639-50
references.pmid: 18687164
references.citation: Rheumatology (Oxford). 2010 Apr;49(4):767-77
references.pmid: 20100793
references.citation: Ann Rheum Dis. 2005 Jul;64(7):995-1002
references.pmid: 15550533
references.citation: Clin Exp Rheumatol. 2005 Nov-Dec;23(6):819-28
references.pmid: 16396700
references.citation: Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1147-52
references.pmid: 20074482
references.citation: Arthritis Rheum. 2006 Sep;54(9):2793-806
references.pmid: 16947627
references.citation: Ann Rheum Dis. 2003 Dec;62(12):1195-8
references.pmid: 14644858